Developer docs
API playgroundTry for free, no card

Search company profiles

Bristol Myers Squibb Foundation

Full company profile

uuid000j4ps

Namestring
Bristol Myers Squibb Foundation
Legal namestring
Bristol Myers Squibb Foundation
Websiteurl
bms.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a publicly traded global biopharmaceutical company (NYSE: BMY). It is a private nonprofit organization headquartered in the United States, with a stated mission to promote health equity and improve health outcomes of underserved populations. The Foundation concentrates its work on two principal program areas: strengthening cancer care delivery in Africa through partnership-based initiatives, and expanding access to life-saving medicines in low- and middle-income countries (LMICs). Programming is structured around the parent company's therapeutic footprint — oncology, hematology, cardiovascular disease — and is delivered through collaborations with healthcare institutions, research organizations, and patient-advocacy groups operating in regions where BMS has limited direct commercial footprint.

The Foundation does not sell products, license intellectual property, or generate commercial revenue. Its funding flows are tied to the parent company's corporate giving and social-impact commitments, and its operational infrastructure is governed under US nonprofit regulation with oversight anchored to Bristol-Myers Squibb Company. The Foundation's technology stack is limited to standard corporate communications, social media engagement, and CRM-driven outreach; advanced capabilities such as AI-driven protein degradation drug discovery referenced in input data are characteristics of the parent biopharmaceutical company, not the Foundation. The Foundation serves three principal beneficiary groups: patients in underserved regions (particularly in Africa and LMICs), healthcare institutions delivering cancer and specialty care in those regions, and broader patient-advocacy and research communities aligned with parent-company therapeutic priorities.

From a business-model perspective, the Foundation functions as a grantmaking and program-delivery vehicle. It does not capture pricing economics, GTM motion, or distribution in the conventional commercial sense; instead, it leverages the parent's global brand recognition, regulatory standing as a 501(c)-aligned entity, and reach through partners to execute health-equity programming. Revenue, budget, and grant-disbursement figures are not disclosed in the input data, leaving financial scale unverified. The Foundation is operationally active and positioned within BMS's broader corporate-responsibility and population-health stack, with continuity tied to the strategic priorities and resourcing capacity of the parent company.

Short descriptiontext

The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a private nonprofit that promotes health equity and improves health outcomes for underserved populations through partnerships strengthening cancer care in Africa and expanding access to life-saving medicines in low- and middle-income countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
health equity philanthropy, cancer care access, global health grants, patient access programs, underserved populations
Industry4 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAC
Community Health, Prevention & Health Education
SECONDARYHLAJAOAC
Global Health Financing Mechanisms & Pooled Funds
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
NAICS code3 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services81321
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Health Equity Philanthropy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

BMS generates revenue primarily through the sale of prescription biopharmaceutical medicines across its therapeutic areas including oncology, hematology, neuroscience, immunology, and cardiovascular diseases. Products include established brands like OPDIVO, YERVOY, REVLIMID, ELIQUIS, and others.

bms.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The Bristol Myers Squibb Foundation is the charitable foundation of Bristol-Myers Squibb Company, focused on promoting health equity and improving health outcomes for underserved populations. It funds partnership-driven programs that strengthen cancer care in regions such as Africa and expand access to life-saving medicines in low- and middle-income countries. The Foundation does not sell commercial products or services; its offerings consist of grant-funded initiatives and institutional partnerships aligned with the parent company's corporate responsibility agenda.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bristol Myers Squibb is a global biopharmaceutical company offering a diverse portfolio of medicines across multiple therapeutic areas including Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular diseases. The company provides both proprietary small molecule drugs and biologic therapies including CAR T-cell therapies. Key products include OPDIVO® and YERVOY® (immunotherapies), ELIQUIS® (anticoagulant), REVLIMID® and POMALYST® (immunomodulatory agents), and innovative cell therapies like ABECMA® and BREYANZI®. The portfolio spans oral, injectable, and infusion formulations targeting serious diseases including various cancers, autoimmune conditions, and cardiovascular diseases. BMS also develops investigational medicines through a pipeline of 50+ compounds across 40+ disease areas.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Healthcare Institutions and Research Organizations
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BMS partners with healthcare institutions, universities, and research organizations globally to conduct clinical trials, collaborative research projects, and clinical studies. These partnerships support drug development across oncology, hematology, neuroscience, immunology, and cardiovascular therapeutic areas.

bms.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Philanthropic arm of Pfizer focused on global health equity, infectious disease, and access-to-medicines initiatives. Directly comparable as another large-cap pharma corporate foundation pursuing health-equity programming in LMICs.

2AbbVie Foundation
TypeDirect peer
Description

Philanthropic arm of AbbVie supporting health equity, patient access, and community health programs. Comparable corporate-foundation structure and health-equity framing.

TypeDirect peer
Description

Foundation of Eli Lilly focused on diabetes, oncology and health-equity programs domestically and globally. Comparable scale, therapeutic focus, and parent-foundation governance.

4Roche Foundation
TypeDirect peer
Description

Roche-affiliated philanthropic entity supporting health access and cancer care initiatives. Comparable therapeutic alignment (oncology focus) and foundation model.

TypeDirect peer
Description

Philanthropic arm of Merck & Co. focused on global health, oncology access, and health workforce capacity building in underserved regions. Comparable mission, structure, and target geographies to BMS Foundation.

TypeDirect peer
Description

Philanthropic arm of J&J operating global health equity programs spanning health workforce, women/children, and infectious disease. Closely comparable in scale, parent backing, and LMIC focus.

TypeBroad incumbent
Description

Largest private health-equity funder globally with deep LMIC health-system investments. Not a corporate foundation, but serves as a benchmark funder/partner shaping the same global health equity space BMS Foundation operates in.

TypeDirect peer
Description

Sanofi's philanthropic vehicle focused on health equity and access in underserved communities. Comparable structure and LMIC orientation to BMS Foundation.

TypeDirect peer
Description

Foundation arm of Gilead Sciences funding HIV, viral hepatitis, and oncology equity initiatives. Comparable structure as a vertically focused biopharma-affiliated grantmaker.

TypeDirect peer
Description

Novartis-affiliated foundation operating population-health and NCD programs in LMICs. Comparable global-health-equity mandate and operating geographies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bristol Myers Squibb Foundation

Health Equity Philanthropybms.com

The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a private nonprofit that promotes health equity and improves health outcomes for underserved populations through partnerships strengthening cancer care in Africa and expanding access to life-saving medicines in low- and middle-income countries.

What Bristol Myers Squibb Foundation does

The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a publicly traded global biopharmaceutical company (NYSE: BMY). It is a private nonprofit organization headquartered in the United States, with a stated mission to promote health equity and improve health outcomes of underserved populations. The Foundation concentrates its work on two principal program areas: strengthening cancer care delivery in Africa through partnership-based initiatives, and expanding access to life-saving medicines in low- and middle-income countries (LMICs). Programming is structured around the parent company's therapeutic footprint — oncology, hematology, cardiovascular disease — and is delivered through collaborations with healthcare institutions, research organizations, and patient-advocacy groups operating in regions where BMS has limited direct commercial footprint.

The Foundation does not sell products, license intellectual property, or generate commercial revenue. Its funding flows are tied to the parent company's corporate giving and social-impact commitments, and its operational infrastructure is governed under US nonprofit regulation with oversight anchored to Bristol-Myers Squibb Company. The Foundation's technology stack is limited to standard corporate communications, social media engagement, and CRM-driven outreach; advanced capabilities such as AI-driven protein degradation drug discovery referenced in input data are characteristics of the parent biopharmaceutical company, not the Foundation. The Foundation serves three principal beneficiary groups: patients in underserved regions (particularly in Africa and LMICs), healthcare institutions delivering cancer and specialty care in those regions, and broader patient-advocacy and research communities aligned with parent-company therapeutic priorities.

From a business-model perspective, the Foundation functions as a grantmaking and program-delivery vehicle. It does not capture pricing economics, GTM motion, or distribution in the conventional commercial sense; instead, it leverages the parent's global brand recognition, regulatory standing as a 501(c)-aligned entity, and reach through partners to execute health-equity programming. Revenue, budget, and grant-disbursement figures are not disclosed in the input data, leaving financial scale unverified. The Foundation is operationally active and positioned within BMS's broader corporate-responsibility and population-health stack, with continuity tied to the strategic priorities and resourcing capacity of the parent company.

Bristol Myers Squibb Foundation firmographics

Firmographics
Name
Bristol Myers Squibb Foundation
Legal name
Bristol Myers Squibb Foundation
Website
https://bms.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
The Bristol Myers Squibb Foundation is the charitable arm of Bristol-Myers Squibb Company, a private nonprofit that promotes health equity and improves health outcomes for underserved populations through partnerships strengthening cancer care in Africa and expanding access to life-saving medicines in low- and middle-income countries.
Ownership category
akta.pro rank

Bristol Myers Squibb Foundation industry classification

Industry
Product category
Health Equity Philanthropy
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAC
Community Health, Prevention & Health Education
SECONDARYHLAJAOAC
Global Health Financing Mechanisms & Pooled Funds
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)

Keywords

  • Health equity philanthropy
  • Cancer care access
  • Global health grants
  • Patient access programs
  • Underserved populations

Where Bristol Myers Squibb Foundation is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Bristol Myers Squibb Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: BMS generates revenue primarily through the sale of prescription biopharmaceutical medicines across its therapeutic areas including oncology, hematology, neuroscience, immunology, and cardiovascular diseases. Products include established brands like OPDIVO, YERVOY, REVLIMID, ELIQUIS, and others.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Bristol Myers Squibb Foundation product offering

Product offering

Core offering

The Bristol Myers Squibb Foundation is the charitable foundation of Bristol-Myers Squibb Company, focused on promoting health equity and improving health outcomes for underserved populations. It funds partnership-driven programs that strengthen cancer care in regions such as Africa and expand access to life-saving medicines in low- and middle-income countries. The Foundation does not sell commercial products or services; its offerings consist of grant-funded initiatives and institutional partnerships aligned with the parent company's corporate responsibility agenda.

Product overview

Bristol Myers Squibb is a global biopharmaceutical company offering a diverse portfolio of medicines across multiple therapeutic areas including Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular diseases. The company provides both proprietary small molecule drugs and biologic therapies including CAR T-cell therapies. Key products include OPDIVO® and YERVOY® (immunotherapies), ELIQUIS® (anticoagulant), REVLIMID® and POMALYST® (immunomodulatory agents), and innovative cell therapies like ABECMA® and BREYANZI®. The portfolio spans oral, injectable, and infusion formulations targeting serious diseases including various cancers, autoimmune conditions, and cardiovascular diseases. BMS also develops investigational medicines through a pipeline of 50+ compounds across 40+ disease areas.

Differentiator

Problem solved

Functional benefit

Companies that use Bristol Myers Squibb Foundation

Customer profile

Segments3 records

Ideal customer profiles1 record

Bristol Myers Squibb Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability2 records

Feature2 records

Bristol Myers Squibb Foundation partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Healthcare Institutions and Research OrganizationscoreStrategic or Co-development PartnerBMS partners with healthcare institutions, universities, and research organizations globally to conduct clinical trials, collaborative research projects, and clinical studies. These partnerships support drug development across oncology, hematology, neuroscience, immunology, and cardiovascular therapeutic areas.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Bristol Myers Squibb Foundation competitors and assessment

Company assessment

Direct peers

  • Pfizer Foundation: Philanthropic arm of Pfizer focused on global health equity, infectious disease, and access-to-medicines initiatives. Directly comparable as another large-cap pharma corporate foundation pursuing health-equity programming in LMICs.
  • AbbVie Foundation: Philanthropic arm of AbbVie supporting health equity, patient access, and community health programs. Comparable corporate-foundation structure and health-equity framing.
  • Eli Lilly Foundation: Foundation of Eli Lilly focused on diabetes, oncology and health-equity programs domestically and globally. Comparable scale, therapeutic focus, and parent-foundation governance.
  • Roche Foundation: Roche-affiliated philanthropic entity supporting health access and cancer care initiatives. Comparable therapeutic alignment (oncology focus) and foundation model.
  • Merck Foundation: Philanthropic arm of Merck & Co. focused on global health, oncology access, and health workforce capacity building in underserved regions. Comparable mission, structure, and target geographies to BMS Foundation.
  • Johnson & Johnson Foundation: Philanthropic arm of J&J operating global health equity programs spanning health workforce, women/children, and infectious disease. Closely comparable in scale, parent backing, and LMIC focus.
  • Sanofi Foundation: Sanofi's philanthropic vehicle focused on health equity and access in underserved communities. Comparable structure and LMIC orientation to BMS Foundation.
  • Gilead Foundation: Foundation arm of Gilead Sciences funding HIV, viral hepatitis, and oncology equity initiatives. Comparable structure as a vertically focused biopharma-affiliated grantmaker.
  • Novartis Foundation: Novartis-affiliated foundation operating population-health and NCD programs in LMICs. Comparable global-health-equity mandate and operating geographies.

Broad incumbents

  • Bill & Melinda Gates Foundation: Largest private health-equity funder globally with deep LMIC health-system investments. Not a corporate foundation, but serves as a benchmark funder/partner shaping the same global health equity space BMS Foundation operates in.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Bristol Myers Squibb Foundation social profiles

Digital presence

Bristol Myers Squibb Foundation compliance and trust

Trust signal

Compliance3 records

Bristol Myers Squibb Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bristol Myers Squibb Foundation leadership team

Management profile

Number of profiles

Bristol Myers Squibb Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bristol Myers Squibb Foundation M&A and investment

M&A and investment

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bristol Myers Squibb Foundation

What does Bristol Myers Squibb Foundation do?

The Bristol Myers Squibb Foundation is the charitable foundation of Bristol-Myers Squibb Company, focused on promoting health equity and improving health outcomes for underserved populations. It funds partnership-driven programs that strengthen cancer care in regions such as Africa and expand access to life-saving medicines in low- and middle-income countries. The Foundation does not sell commercial products or services; its offerings consist of grant-funded initiatives and institutional partnerships aligned with the parent company's corporate responsibility agenda.

Is Bristol Myers Squibb Foundation a public or private company?

Bristol Myers Squibb Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Bristol Myers Squibb Foundation founded?

Bristol Myers Squibb Foundation was founded in 2013. It employs 101 to 250 people.

Where is Bristol Myers Squibb Foundation based?

Bristol Myers Squibb Foundation is headquartered in San Diego, United States, in the North America region.

How does Bristol Myers Squibb Foundation make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Bristol Myers Squibb Foundation's main competitors?

Direct peers on record are Pfizer Foundation, AbbVie Foundation, Eli Lilly Foundation, Roche Foundation, Merck Foundation, Johnson & Johnson Foundation, Sanofi Foundation, Gilead Foundation and Novartis Foundation. Bill & Melinda Gates Foundation is listed as a broad incumbent.

Does Bristol Myers Squibb Foundation have an API?

No public API is recorded for Bristol Myers Squibb Foundation.

What industry is Bristol Myers Squibb Foundation in?

Bristol Myers Squibb Foundation's product category is Health Equity Philanthropy. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGACAC, Community Health, Prevention & Health Education. Its NAICS code is 813211 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialNew Program Helps Louisiana Social Workers Advance Toward Clinical LicensureThe Louisiana Public Health Institute, with the National Mental Health Corps and Bristol Myers Squibb Foundation, launched the Louisiana Behavioral Health Workforce Catalyst to help social workers advance to clinical licensure. The free program offers financial assistance, exam prep, and virtual supervision, aiming to address over 4,000 unlicensed MSWs in the state.New Orleans City BusinessLouisiana program aims to expand mental health workforce | New Orleans CityBusinessThe Louisiana Public Health Institute launched a program to help social workers obtain clinical licenses, addressing workforce shortages. It estimates 5,000 Louisiana social work graduates remain unlicensed and offers free supervision, exam prep, and financial aid. The initiative, supported by the National Mental Health Corps and Bristol Myers Squibb Foundation, targets rural and underserved communities.YahooTransforming Lung Cancer Care & Early Detection in TanzaniaDr. Nestory Masalu, Head of Oncology at the Catholic University of Health and Allied Sciences/Bugando Medical Center, discusses integrating molecular testing and community screening to shift lung cancer diagnoses to earlier stages in Tanzania. The initiative, supported by the Bristol Myers Squibb Foundation, partners with the Ministry of Health and the National TB and Leprosy Programme to scale the care model.YahooEuropean Equities Traded in the US as American Depositary Receipts Decline in Monday TradingEuropean equities traded in the US declined as American depositary receipts started the week lower on Monday. Despite some European markets closing mostly higher, the article highlights an overall cautious trading tone and mentions AstraZeneca's reported merger talks with Bristol Myers.MarketScreenerBristol Myers buys Nvidia's latest AI computing system for drug researchBristol Myers has purchased Nvidia's latest AI computing system for drug research. The article details Nvidia's business scope, products, and revenue distribution, along with financial analyst ratings and stock information.3BL MediaBristol Myers Squibb Foundation Awards Grant to PATHThe Bristol Myers Squibb Foundation has awarded a grant to PATH to launch an initiative addressing hemoglobinopathies, particularly Thalassemia, in India where nearly 25% of the global β-thalassemia burden exists with 10,000–15,000 children born with the condition annually. The program will be implemented across Maharashtra and Madhya Pradesh states, focusing on strengthening screening, prevention, capacity-building for healthcare workers, and coordinated care systems including blood transfusions and bone marrow transplants. The initiative aims to directly impact over 1.8 million pregnant women, newborns, and families of affected individuals through integrated screening services.BmsBristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate FoundationThe Bristol Myers Squibb Foundation announced a $1 million donation to the Patient Advocate Foundation to expand its capacity for delivering case management and financial assistance to patients with chronic illnesses. The funding aims to support the nonprofit's ability to help vulnerable individuals navigate healthcare access barriers and reduce out-of-pocket medical expenses. This contribution was made in honor of Global Patient Week at Bristol Myers Squibb.PATHPATH awarded Bristol Myers Squibb Foundation grant to tackle hemoglobinopathies in IndiaPATH and the Bristol Myers Squibb Foundation announced a grant to address hemoglobinopathies in India, focusing on Thalassemia. The initiative will work with Maharashtra and Madhya Pradesh to screen over 1.8 million pregnant women, newborns, and families, aiming to improve care access and capacity.https://www.wctv.tvPartnership brings licensed therapists to Decatur County for mental health-related patrol callsDecatur County Sheriff's Department will partner with Georgia Pines to deploy licensed counselors on mental health patrol calls, supported by a $500,000 grant from Bristol Myers Squibb Foundation. The program, launching August 20, aims to reduce arrests and hospital visits, with an outreach component for jail releases.